Lifecore Biomedical, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5147661046
USD
7.77
0.05 (0.65%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Lifecore Biomedical, Inc. stock-summary
stock-summary
Lifecore Biomedical, Inc.
Pharmaceuticals & Biotechnology
Landec Corporation designs, develops, manufactures and sells a range of health and wellness products for food and biomaterials markets. The Company licenses technology applications to partners. The Company operates through three segments: Packaged Fresh Vegetables, Food Export and Biomaterials. The Packaged Fresh Vegetables segment markets and packs specialty packaged whole and fresh-cut fruit and vegetables, the majority of which incorporate the BreatheWay specialty packaging for the retail grocery, club store and food services industry. The Food Export segment is engaged in the purchase and sale of whole commodity fruit and vegetable products primarily to Asia. The Biomaterials segment sells products utilizing hyaluronan, a polysaccharide that is distributed in the extracellular matrix of connective tissues in both animals and humans, and non-hyaluronan (HA) products for medical use primarily in the ophthalmic, orthopedic and other markets.
Company Coordinates stock-summary
Company Details
5201 Great America Pkwy Ste 232 , SANTA CLARA CA : 95054-1126
stock-summary
Tel: 1 650 3061650
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 26 Schemes (13.41%)

Foreign Institutions

Held by 27 Foreign Institutions (2.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Craig Barbarosh
Independent Chairman of the Board
Dr. Albert Bolles
President, Chief Executive Officer, Director
Mr. Jeffrey Edwards
Director
Mr. Joshua Schechter
Director
Mr. Patrick Walsh
Director
Ms. Deborah Carosella
Independent Director
Ms. Katrina Houde
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
36 Million
(Quarterly Results - May 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 273 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

2.46

stock-summary
Return on Equity

-86.17%

stock-summary
Price to Book

5.75